Missions accomplished?
Search results for: fracture
Reading Rheum
Handpicked Reviews of Contemporary Literature
Key Grassroots Opportunity
Congress is in recess August 11 through September 5. During this time, members of Congress are meeting with constituents in their district offices, so this is a great opportunity for you to…
Healthy Bones in Children
Recent research provides insight into this important area of public health
RheumPAC: One Year, One Contribution, One Opportunity
Responders to the recent ACR membership survey emphasized the importance of political advocacy for their practices and institutions. RheumPAC, the ACR’s political action committee, was created in February 2007 to focus on the legislative issues affecting the rheumatology community.
Glucocorticoid-Induced Osteoporosis
Osteoporosis is a condition of weak bone caused by a loss of bone mass and a change in bone structure. Glucocorticoid-induced osteoporosis is a form of osteoporosis caused by taking glucocorticoid medications, such as prednisone (Deltasone, Orasone, etc.), prednisolone (Prelone), dexamethasone (Decadron, Hexadrol), and cortisone (Cortone Acetate). These medications are used to help control many rheumatic diseases, including RA, systemic lupus erythematosus, and polymyalgia rheumatica.
Physician Quality Reporting Initiative (PQRI) Changes for 2008
CMS has announced alternative reporting periods and reporting criteria for the 2008 Physician Quality Reporting Initiative (PQRI).
American College of Rheumatology (ACR) on Capitol Hill
“By tomorrow night, there will be so many more people on Capitol Hill who know—and are sensitive to—rheumatology and the issues that impact you and your patients. There is no substitute for what you are doing,” says Martha M. Kendrick, a partner at Patton Boggs, LLP, the ACR’s lobbying firm. This is what she told the physician, health professional, and patient participants of the ACR’s 2008 “Advocates for Arthritis” advocacy event—termed a fly-in—before they took their personal stories to the lawmakers on Capitol Hill.
Dr. Wolfe & the National Data Bank for Rheumatic Diseases (NBD)
A private database becomes a national resource
The Line Between Boost and Ban
What makes a performance-enhancing drug taboo?
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- 43
- Next Page »